Sarah says that while some patients do benefit from seeing multidisciplinary hospital teams, many are easily managed in practice and benefit from local care.
Oncotails offers early intervention at the time of diagnosis, either with advice for the GP or an owner consultation to discuss treatment options and likely prognosis, and to answer those difficult questions.
This, says Sarah, frees up time for the local vet who keeps management of the case but with the expert guidance of a specialist.
https://www.oncotails.com
The tool forms part of a national tumour registry built by Liverpool’s Veterinary Data Science Group with the University of Las Palmas de Gran Canaria using pathology records from veterinary diagnostic laboratories.
The registry aggregates more than one million tumour diagnoses across more than 200 breeds and 150 tumour types.
Users of the dashboard can select a tumour type and species and view how relative risk varies across demographic groups within the dataset.
Results are presented as odds ratios against a reference group.
The platform is publicly accessible and designed to allow vets, researchers and owners to explore patterns in the data.
Professor David Killick, veterinary oncologist at the University of Liverpool, said most veterinary cancer diagnosis data historically sits in private laboratories and is not easily accessible for research.
“It is important to understand risks for cancers — and this applies to pets too.
“But for dogs and cats, most cancer diagnosis data sit in private veterinary labs, inaccessible for research.
“Working through SAVSNET, our Small Animal Veterinary Surveillance Network, we wanted to see whether we could bring together large volumes of these data into one meaningful, research-ready database.”
The dataset enables analysis of tumour risk across large numbers of breeds and cancers that have previously been difficult to study due to fragmented reporting.
An analysis of four major canine tumours using the registry has been published in the Veterinary and Comparative Oncology1.
The registry will continue to expand as additional laboratories contribute data.
The project is funded by the Petplan Charitable Trust.
https://public.tableau.com/app/profile/savsnet.at.liverpool/viz/SAVSNETtumourregistry/frontpage
Reference
The new study will examine the genetic changes that occur in osteosarcoma tumours.
By understanding which genes drive the disease, researchers hope to identify biomarkers – genetic clues that could help diagnose the cancer earlier, predict prognosis for individual patients, and ultimately lead to new treatment options.
The study is looking for dogs with a confirmed or suspected diagnosis of osteosarcoma, whose treatment plan includes surgical removal of the tumour at the QVSH.
With the owner’s permission, tissue samples will be collected from the amputated limb after surgery, as well as from nearby healthy tissue for comparison.
The researchers say participation involves no additional procedures, discomfort, or hospital visits for dogs, and there is no cost to owners for the research elements of the study.
Dr Louise Van Der Weyden, study co-lead at the Wellcome Sanger Institute, said: “Our new study aims to apply genomic sequencing techniques, which have benefited humans, to canine osteosarcoma to uncover what drives these bone tumours and gain a deeper understanding of why they happen.
"We hope that by doing so, we can pave the way for the development of potential biomarkers to help early diagnosis and possibly provide future treatment options for dogs who currently have no cure.”
https://www.hospital.vet.cam.ac.uk/news/new-research-improve-diagnosis-and-treatment-canine-osteosarcoma
oncology@vet.cam.ac.uk
This, says the company, highlights a missed opportunity for earlier cancer detection, which in turn limits the ability of veterinary teams to improve medical outcomes for their patients.
243 veterinary professionals took part in the survey, most of whom HT Vista says were general practitioners.
On average, they reported seeing 13.5 dermal and subcutaneous masses per vet per week, less than six of which lead to a diagnosis.
HT Vista says around 15% of these lumps will be malignant.
Veterinary oncologist Gillian Dank said: “Every week, thousands of dogs leave practices with undiagnosed masses.
"While many are benign, others are malignant, and delaying diagnosis can mean lost treatment opportunities and poorer prognoses.”
The number one reason why respondents said they don't test more widely is the assumption that a mass is benign by its gross characteristics, followed by owner concerns around cost, time constraints during consultations, and limited access to in-house cytology.
Vista HT Chief Commercial Officer Asher Fink and Managing Director Liron Levy-Hirsch will be presenting “20 dogs in your waiting room with lumps and bumps – how do you spot the 3 with cancer?" at the London Vet Show on 20th November from 1–1:50pm in Exhibitor Showcase Theatre 2
https://info.ht-vet.com/lump-and-bump-survey-results
https://www.cliniciansbrief.com/continuing-education/syllabus/lesson/cracking-code-lumps-bumps-fast-efficient-diagnosis-everyday-practice
https://london.vetshow.com/conference-programme-2025/session-title-coming-soon-38
Photo: www.depositphotos.com
The new oncology department has a dedicated chemotherapy room, access to a variety of chemotherapy drugs and a fully equipped operating theatre – offering soft tissue and orthopaedic surgery services for surgical oncology cases.
The department also has access to high frequency ocular ultrasound, magnetic resonance (MRI), and computed tomography (CT) scan equipment.
The service will be led by residency-trained clinician in Small Animal Oncology, Nina Vigevani DVM MRCVS.
She graduated in 2019 from the University of Milan, completed a rotating internship and worked in general practice in Milan, before moving to the UK to start on an oncology internship at a referral practice in the South of England.
Prior to moving to Chestergates, she completed her Residency in Small Animal Oncology at the University of Liverpool.
To refer a case: https://chestergates.org.uk/referral-services.
The new resource is designed to help dog owners understand the risks of cancer, recognise the importance of early detection, and learn how HT Vista’s cancer detection device supports veterinary teams in screening suspicious masses.
It includes guidance on the early warning signs of cancer in dogs and explains how acting quickly can improve outcomes.
Dr Liron Levy-Hirsch, Veterinary Surgeon and Managing Director at HT Vista said: “We believe informed pet owners are key to driving earlier diagnosis.
"This new page is all about bridging the gap between innovative veterinary technology and the people it’s designed to support.
"By empowering pet owners with clear and trustworthy information, we hope to strengthen understanding of the diagnostic process, support clinical decision-making, and ultimately help more dogs receive timely treatment.”
www.ht-vet.com/petowners
BraveBites contains protein, fish oil (rich in omega-3) and prebiotics.
The snack, which was developed with a veterinary nutritionist, has a soft texture and high palatability.
Camille, who worked for a year at Fitzpatrick Referrals, said: “In dogs undergoing cancer treatment, decreased appetite and weight loss are common.
"They negatively affect both prognosis and quality of life.
“Owners were constantly asking what they could still give their dog when food refusal started.”
Camille says that in a field test across 40 veterinary clinics in Belgium and the Netherlands, over 95% of oncology patients accepted the snack well, with a reported improvement in appetite and quality of life
BraveBites is available direct to vets, with educational material, client brochures, and quality-of-life monitoring tools.
http://www.bravebitespetfood.com
The new platform offers video tutorials, podcasts, webinars, scientific studies, blogs and downloadable resources, all designed to ensure users understand how the HT Vista screening device can support their day-to-day work.
Users can also ask for a free one-on-one training call with HT Vista for personalised guidance.
HT Vista’s Managing Director, Liron Levy-Hirsch said: “We’re excited to introduce this new platform for veterinary professionals alongside our latest diagnostic update to the device.
"Our goal with HT Vista Academy is to support users in expanding their expertise, not just in operating the device but also in understanding the technology behind it and learning the best practice of dermal and subcutaneous mass management.
"By offering valuable educational resources and hands-on support, we hope to enhance the overall experience for veterinary teams and, ultimately, the care they provide to their patients.”
The company says the screening device is being widely used in nurse clinics around the world and its academy is suitable for both vets and veterinary nurses.
www.ht-vet.com/academy
The updated indications reflect the recognition that Stelfonta may be used in any case where surgery may not be an option:
For the treatment of non-metastatic (WHO staging) mast cell tumours that are either non-resectable or those that are resectable but where surgery is not considered the best option, specifically: cutaneous mast cell tumours (located anywhere on the dog) and subcutaneous mast cell tumours located at or distal to the elbow or the hock.
Tumours must be less than or equal to 8 cm 3 in volume, and must be accessible to intratumoral injection.
Neil Mottram MRCVS, Technical Manager at Virbac said: “Stelfonta offers veterinary surgeons a medical option for the successful elimination of mast cell tumours.
"The extended labelled indication demonstrates the wide variety of cases that can benefit where medical treatment is preferred, such as; tumour factors (location and size) making surgical margins difficult, patient factors (concurrent disease and risk of anaesthesia), clinic factors and the simplification of this medical treatment and owner factors, where there is a preference to avoid surgery."
Stelfonta is administered by injection directly into the tumour mass and Virbac say that generally, dogs do not require sedation or local or general anaesthesia during treatment.
The active ingredient, Tigilanol tiglate, works largely through specific protein kinase c (PKC) activation, in which it locally stimulates the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
www.virbac.co.uk
The Elekta Infinity linear accelerator is the only one of its kind for pets in England.
CVS says it allowing the centre to offer “cutting edge” image-guided radiation treatments for cancer in cats and dogs – meaning fewer, shorter sessions, fewer side effects and the best possible chance of improved outcomes for the animal.
Delphine Holopherne-Doran, Clinical Director at Bristol Vet Specialists, said: “Our new hospital is now at the forefront of cancer care in animals.
"We have invested in this state-of-the-art technology to bring cancer treatment in pets to the next level.
“Our unique linear accelerator allows us to offer advanced image-guided treatments - for example intensity-modulated or stereotactic radiation therapy.
"The advantage of these treatments is that high dose rates of focused beams are delivered with high precision over a shortened treatment course, with greater safety for the patient’s healthy tissue.
“It has now drawn many tumours into the realm of treatability, it is improving the quality of life for patients, and it is making it easier for owners to manage their pet’s treatment and aftercare.”
Still, the installation of the linear accelerator will probably have cost the same again, and then you've got the running costs.
That's not an inconsiderable cost per patient.
The HT Vista device is used by vets and vet nurses to screen dermal and subcutaneous masses on dogs.
The company says that with a negative predictive value of 98% clinicians can confidently classify a mass as benign without the need of further invasive tests.
HT Vista also says that, according to a recent client survey, the main features which practices value are the nurse-led ability which is maximising nurse clinics and streamlining efficiency, justification in sampling masses even when they feel innocuous, and the rapid speed of image acquisition and results.
To be in with a chance of winning the device and subscription, delegates must attend the 15-minute Ultra Demo at stand B300 on Friday 22nd March at 4pm.
The app allows practices to submit results along with cytology and histopathology results in order to help train the AI algorithm and improve its accuracy from an original sensitivity of 85% and negative predictive value of 97%.
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The HT app has provided us with over 700 additional validated scans to analyse this year alone.
"The validation process is well controlled, whereby we use the lab results to tag the scans as benign or malignant and let the algorithm know if it was correct or not.
"The more we train the algorithm the more accurate it becomes, and it is extremely exciting to see the sensitivity increase to 90% and the NPV to 98%.”
HT Vista says the app was developed to meet demand from clinics.
Liron said: "By having a portal to upload lab results alongside the device’s results not only do we further improve the device, but we also increase confidence among our vets and nurses that the device is a reliable tool.
https://ht-vista.uk
The company says the Elekta Infinity linear accelerator is the only one of its kind for pets in England.
It features a multi-leaf collimator for very accurate shaping of the radiation beam and a six-degrees-of-freedom couch top designed so the patient can be positioned to reduce or eliminate radiation doses to critical organs.
CVS says the new machine will allow the centre to offer cutting edge treatments such as stereotactic radiation therapy, where high dose rates of focused beams are delivered with high precision over a shortened treatment course.
This, the company claims, will mean fewer, shorter sessions, fewer side effects and the best possible chance of improved outcomes for the animal.
Delphine Holopherne-Doran, Clinical Director at Bristol Vet Specialists, said: “Our new hospital will be at the forefront of cancer care in animals.
“The linear accelerator is state of the art, and allows us to offer advanced, image-guided radiation treatments - for example intensity-modulated or stereotactic radiation therapy.
"The advantage to these treatments is that they will allow a more “hard-hitting” treatment of the tumour, with greater safety for the patient’s healthy tissue.
"It will draw many tumours into the realm of treatability.”
Based at Central Park, Avonmouth, Bristol Vet Specialists referral hospital is due for completion this Autumn.
There will be 20 presentations from some of the world's leading experts, covering topics such as detection and diagnosis, advances in veterinary oncology, supportive care for the cancer patients, how to build a partnership with pet owners and, of course, feeding the cancer patient.
The presentations will be streamed live and available on demand afterwards, at https://learn.hillsvet.com/en_GB/hills-global-symposium-2023
Dr. Iveta Becvarova, Senior Director of Global Academic & Professional Affairs at Hill's Pet Nutrition said: "This year’s Hill’s Global Symposium will offer the latest advancements and innovations to help veterinary professionals support and counsel their clients, and provide the best care possible to the pets in their care."
55 veterinary surgeons took part in the survey, which also found that only 37% of clinicians use FNA and cytology when investigating a suspected lipoma.
According to the survey, the biggest barriers to further investigations of lumps and bumps were cost (50%), short consult time (23%) and confidence in results (20%).
HT Vista, which earlier this year launched a cancer screening device for dogs which uses heat diffusion technology and AI to differentiate between benign skin masses and other tumours, is urging more practising vets to use an accurate screening process for early detection of malignant masses.
Dr. Gillian Dank, Board Certified Oncologist and Chief Veterinary Officer at HTVet, said: “There is no way to know that a mass is a lipoma based on palpation alone.
"The fact that a mass is subcutaneous, soft and circumscribed is not exclusive to lipoma and it could be a number of things including a mast cell tumour or sarcoma.
"On average a veterinary practice sees over 500 dermal and subcutaneous masses each year.
"We know anecdotally, and surveys like this confirm, that not every mass is aspirated – and that is why there is need for the HT Vista screening device.
"Every mass that comes in should be properly examined.”
“It’s interesting to see that the more experienced a clinician is, the less confident they are in diagnosing from palpation and this shows us that with experience we understand that our hands are not enough.”
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The survey showed that vets are conscious of the cost to clients, and also feel pressured due to time.
"We have developed the HT Vista to complement FNA and cytology, and hope clinicians find it a useful tool.
"Firstly, it is quick and affordable to scan, and for those masses that are benign it removes the need for unnecessary FNA’s.
"Secondly, vets are often wary of cost, however if a mass is scanned and the results indicate that further investigation is needed, there is more rationale to spend the extra money to get the cytology results.
"Finally, the device can offer complete confidence that malignancies are not being missed, and if a mass is malignant a prompt treatment plan can be initiated.”
https://www.vetreport.net/wp-content/uploads/2023/08/Lump-and-Bump-Survey-2023FINAL.pdf
The new suite offers chemotherapy and radiotherapy treatment facilities under one roof, including a linear accelerator (LINAC) which enables treatment of tumours previously considered untreatable.
Southfields has two full-time client-facing specialists in radiation oncology and two on-site, full-time double-boarded medical and radiation oncologists, along with dedicated radiotherapy technicians and therapeutic radiographers.
RCVS and European Specialist Sarah Mason, Southfield's lead in general oncology, said: “Southfields is already renowned as being the leader in cancer treatment for small animals in the UK and the opening of our dedicated oncology and radiotherapy suite takes patient care to an even higher level.”
www.southfields.co.uk
For those new to the club, the idea is that every two weeks, we pick an article in Veterinary Practice and invite the author to join us on VetSurgeon.org, so that you can ask questions and discuss the subject with one another.
As a bonus, you can claim time spent reading or participating in the discussion towards your annual CPD requirement (press the claim CPD button at the top right of the discussion thread).
For this first discussion of 2023, author Andy Yale, an RCVS and European Veterinary Specialist in Small Animal Oncology and Lecturer in Veterinary Oncology at the RVC, will be joining us for a week to answer questions about 'Diagnosis and treatment of common canine oral tumours'.
To take part, first read Andy's article here: https://www.veterinary-practice.com/article/common-canine-oral-tumours.
Then come and join the VetSurgeon Clinical Article Club and post your questions or discussion points here: https://www.vetsurgeon.org/associations/vetsurgeon-clinical-article-club/
VetSurgeon.org Editor, Arlo Guthrie said: "I hope lots of you will come and join in. It really is a great opportunity to learn from specialists and from each other in a professional, moderated forum, where you can be confident of a friendly welcome.”
To find out about the RVC’s internationally recognised veterinary oncology team and the services it offers, visit: https://www.rvc.ac.uk/small-animal-vet/specialist-referrals/clinical-services/veterinary-oncology
The authors say that the prognosis for dogs with stage II Kiupel high-grade cutaneous mast cell tumours has historically been considered poor.
However, the removal of metastatic regional lymph nodes in more recent research has been associated with a better outcome in canine cutaneous mast cell tumours.
For this study1, dogs with a histological diagnosis of overt lymph node metastasis that underwent lymphadenectomy (n = 31) were compared with those with a cytological diagnosis of regional lymph node metastasis, that did not undergo excision (n 18).
The study was a multi-institutional retrospective cohort study, using electronic medical records from four European institutions to identify dogs for inclusion.
The study found that dogs with Kiupel high-grade cutaneous mast cell tumours undergoing lymphadenectomy of HN3 lymph nodes as part of their primary surgery in addition to adjuvant medical treatment had a significant improvement in time to progression and survival time compared with those dogs not undergoing the procedure.
Lack of lymphadenectomy was the only variable significantly associated with a higher risk of nodal progression.
Dogs underwent lymphadenectomy of one peripheral lymph node in most cases.
The authors says that a higher number of lymph nodes or the removal of intracavitary lymph nodes might be associated with an increased incidence of postoperative morbidity.
They add that the findings warrant further exploration of the effect of surgical extirpation of metastatic sentinel lymph nodes and the number of lymph nodes removed on outcome in dogs with Kiupel high-grade cutaneous mast cell tumours.
Nicola Di Girolamo, Editor of JSAP said: “It is really encouraging to see collaborations from multiple institutions like the study presented here.
"Including multiple institutions in a retrospective cohort study, does not only ensure a higher sample size, but also ensure a higher generalisability of the results.
"Meaning that it is more likely that the differences observed in this study are also going to be observed at different practices and with different clinicians.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13525
Virbac points to research showing that MCTs are the most common form of skin cancer in dogs, accounting for up to 21% of skin cancer cases1.
This, says the company, means that understanding the challenges surrounding mast cell tumour diagnosis, work up (including the various prognostic panels) and treatment selection for mast cell tumour cases is vital.
The session, entitled ‘Fundamentals of Mast Cell Tumour Management’, will conclude with a review of Stelfonta, walking through cases and how to get the best results.
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "We know that vets are facing webinar fatigue.
"We therefore hope that this brand new style of online learning on one of the most common canine cancers will be more engaging, whilst still delivering high quality CPD."
To register for the live event, visit: https://tinyurl.com/mct-masterclass
For more information, speak to your Virbac Territory Manager, or visit vet-uk.virbac.com/stelfonta
The new GPCert programme, led by course director Owen Davies MA VetMB MVetMed MANZCVS (Small Animal Medicine) DipACVIM (Oncology) (pictured right), consists of 12 modules covering key clinical subjects in veterinary oncology delivered over 14 months.
Each module consists of nine lessons, two case studies, course notes and weekly summary videos.
Lessons are supported by notes and videos, quizzes and a forum tutored by leading specialists.
Owen said: “Half of all canine cancers are treatable if caught early enough and new treatments are continuously being researched.
"The programme will guide delegates through the latest knowledge in state-of-the-art, compassionate cancer care for animals, helping them to provide safe and comprehensive diagnostics and treatments.”
For more information, visit: https://www.improveinternational.com/uk/course/oncology-online-learning/
The Oncology Working Group, winningly styled as 'WOW', says it hopes that the glossary will give owners a clearer understanding of the diagnosis and management choices they have, and help them discuss care with their veterinary surgeon from a more informed perspective.
The glossary is the first output from the WOW Group which was formed in 2021 to raise awareness of the latest thinking in cancer therapy and promote best practice globally.
The glossary is available to download free from the WSAVA website at: https://wsava.org/wp-content/uploads/2021/11/Glossary-WOW-13.11.2021.pdf
WOW Group Member Professor Nick Bacon, a RCVS-Recognized Specialist in Small Animal Surgery (Oncology) and a European Specialist in Small Animal Surgery, said: “Cancer has a language all of its own and, during our early WOW Group discussions, it became obvious that, in order to improve communication between veterinary professionals and owners, there was an urgent need for a globally accessible resource to help owners better understand cancer terminology.
“Our Oncology Glossary is the result.
"We hope it will enable owners to feel on a more equal footing when they are discussing their pet’s condition with veterinary professionals.
"We hope it will also increase the consistency and effectiveness of communication about veterinary oncology globally.”
He added: “We will update the Oncology Glossary regularly and are now working on the development of further practical and easy-to-use tools to support veterinarians working in this rapidly evolving area of veterinary medicine.
"In the meantime, more resources are available on our web page at https://wsava.org/committees/oncology-working-group/”
This, says the company, highlights the need for increased awareness of MCTs, which, accounting for up to 21% of skin cancer cases2 in dogs, are the most common form of canine cutaneous neoplasia.
The incidence of MCTs is highest in dogs aged 6 to 10 years old3,4 with predisposition in some of the UK’s most popular breeds such as Labradors, French Bulldogs, Staffordshire Bull Terriers and Golden Retrievers.
Virbac says that until the launch of Stelfonta, surgical removal of tumours was the standard of care, but surgery can pose challenges for the veterinary surgeon, such as the accessibility of the tumour in order to obtain sufficient margins and anaesthetic risks, particularly in senior and brachycephalic pets.
Apparently, however, 77% of delegates at London Vet Show said they were either likely or very likely to use Stelfonta on their next mast cell tumour case.
To help veterinary professionals and pet owners identify skin masses, Virbac has created a range of resources available at: vet-uk.virbac.com/stelfonta/education.
References
BlueSky says that conventional treatment for equine sarcoids, which are induced by tumour antigens E6 and E7 of the bovine papillomavirus, have only limited effect and typically result in the recurrence of the tumours.
However, research published by the company in PLoSONE1 showed that sarcoids treated with delNS/E6E7 were completely and permanently eliminated.
For the study, 29 horses were treated with different regimes involving direct injection into the tumours over three years.
Visible and very significant regression of the sarcoids was achieved in 20 of the treated horses, and 100% regression of the sarcoids in 10 equine patients.
Thomas Muster, CEO of BlueSky Immunotherapies said: "The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform."
In addition, the systemic delNS-mediated immune stimulation eliminated non-injected sarcoids and the papillomavirus that caused the sarcoids.
Thomas added: "We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way."
This brings the total number of oncology specialists to four, within a service comprising 12 oncology professionals.
After getting her bachelor’s degree in biology from Duke University, Sarah (pictured right) enrolled at the University of Pennsylvania School of Veterinary Medicine, from which she graduated summa cum laude (with highest honours) in 2017.
Sarah stayed on at Penn to complete an internship in small animal medicine and surgery followed by a residency in medical oncology.
She became a diplomate of the American College of Veterinary Internal Medicine in 2021 and joined the team at Davies in October 2021.
Sarah said: “I joined Davies for the opportunity to collaborate with specialists spanning all aspects of veterinary medicine.
“This allows me to provide the best care for my patients and contribute to the future of veterinary medicine.
"It is a privilege to work with so many kind, motivated and intelligent individuals that share these same goals.”
The service uses an Xstrahl 100 superficial radiotherapy system, a £150,000 piece of equipment installed by Paragon after it was used successfully in the USA by the hospital's medical and radiation oncology specialist, Dr Rodney Ayl.
Rodney (pictured right) says the new equipment will transform the way Paragon can treat skin cancers, dermatological disorders and some other common superficial conditions.
He said: “This is a very exciting development for us and our clients because Xstrahl systems have been used so successfully in human medicine for many years.
“This prompted us to explore adapting the SRT system for veterinary use in the UK and we hope to collaborate with Colorado State University, which has a similar unit, to develop protocols for pets.
“We believe this will be a significant advance in the treatment and care of animals and we’re delighted to be at the forefront of introducing this new service.
“It is the only one of its kind for pets in the UK and there are very few units like this anywhere in the veterinary industry, so it really is an important move forward.”
Xstrahl radiotherapy systems were originally designed for the treatment of skin cancer, dermatological disorders, certain types of benign disease and some palliative care in humans.
Rodney says that having adapted the SRT system for animals will transform their treatment and the logistics and cost of getting radiation therapy for superficial skin conditions.
He added: “Superficial radiotherapy is particularly useful for treating some types of skin cancer where it may be preferable to surgery as it can deliver excellent non-invasive outcomes with curative or palliative intent.
“The treatment is less stressful from the outset and, thanks to its mechanism of action, it is also pain-free.
“Its use of different size cones, directly over the lesion, minimises effects on healthy skin and the fast treatment means a large reduction in time and impact on the patient’s day-to-day life, while providing a highly-effective treatment.
“The machine’s flexibility also makes it particularly suited for treating multiple lesions that are difficult to access, such as the head and neck, without changing patient positioning.
“The Xstrahl 100 system will help us to respond to the growing demand for radiation treatment and we can treat these patients on an outpatient basis, helping us to reduce surgical and hospitalisation costs.
“The technology is a real winner. It is easy to use and helps us to deliver safe and effective radiotherapy to our animal patients.
“It provides a quicker, easier, cheaper and non-invasive alternative for superficial tumours, especially in geriatric patients where surgery is not always an option. We’re looking forward to seeing the positive results here at Paragon.”
For more information, visit www.paragonreferrals.co.uk.